Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | ALAD | P13716 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8634171 | 0.98 | DAO (0.47) | DAOCA1CA2TDP1MIF | |
| SCHEMBL8634167 | 0.82 | MIF (0.46) | MIFALDH1A1CYP3A4MEN1KMT2A | |
| SCHEMBL2789975 | 0.82 | MAPT (0.48) | MIFTP53ALDH1A1CYP3A4MEN1 | |
| SCHEMBL28263654 | 0.82 | SMN1; SMN2 (0.50) | TDP1MIFALDH1A1CYP3A4ALOX15 | |
| SCHEMBL1844829 | 0.82 | MIF (0.43) | MIFALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13497519 | 0.82 | DAO (0.50) | DAOMIFALDH1A1ALADMEN1 | |
| SCHEMBL6142322 | 0.79 | ALAD (0.61) | CA1CA2TDP1ALDH1A1ALAD | |
| SCHEMBL18430372 | 0.78 | MIF (0.40) | MIFALDH1A1CYP3A4MEN1KMT2A | |
| SCHEMBL11213610 | 0.78 | KMT2A (0.49) | MIFTP53ALDH1A1CYP3A4MEN1 | |
| SCHEMBL6694136 | 0.78 | ALDH1A1 (0.56) | MIFALDH1A1CYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107400110-A | The impurity B of Raltitrexed and its preparation and application | 南京正大天晴制药有限公司 | 2017-11-28 | — | — | CN | claimed |
| EP-0186252-B1 | USE OF THIOPHENE COMPOUNDS FOR THE MANUFACTURE OF A MEDICAMENT AGAINST TUMOURS | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1992-04-01 | — | — | EP | claimed |
| CN-119371425-A | Nitrogen-containing heterocyclic compound, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-116023359-B | Synthesis method of aminothiophene compound and aminothiophene compound | 上海泰坦科技股份有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-117486882-B | Matrine alkaloid derivative and application thereof in preparation of multi-target multi-organ tissue cell injury inhibitor | 吉林农业大学 | 2024-06-11 | — | — | CN | disclosed |
| CN-117486882-A | Matrine alkaloid derivative and application thereof in preparation of multi-target multi-organ tissue cell injury inhibitor | 吉林农业大学 | 2024-02-02 | — | — | CN | disclosed |
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2023-09-21 | — | — | US | disclosed |
| CN-116023359-A | Synthesis method of aminothiophene compound and aminothiophene compound | 上海泰坦科技股份有限公司 | 2023-04-28 | — | — | CN | disclosed |
| CN-113666907-A | Method for rapidly preparing 4-nitrothiophene-2-formic acid based on microchannel reaction technology | 都创(上海)医药开发有限公司 | 2021-11-19 | — | — | CN | disclosed |
| CN-109283263-B | Determination method for Raltitrexed synthesis quality control | 南京正大天晴制药有限公司 | 2019-06-25 | — | — | CN | disclosed |
| EP-0592167-A1 | Antibiotic pyrrolidinylthiopenem derivatives | ZENECA LIMITED (GB) | 1994-04-13 | — | — | EP | disclosed |
| EP-0586663-A1 | CARBAPENEM DERIVATIVES AS ANTIBIOTICS AND INTERMEDIATES THEREOF | ZENECA LIMITED (GB) | 1994-03-16 | — | — | EP | disclosed |
| CN-1077957-A | Antimicrobial compounds | ZENECA LTD (GB) | 1993-11-03 | — | — | CN | disclosed |
| WO-1993019070-A1 | CARBAPENEM DERIVATIVES AS ANTIBIOTICS AND INTERMEDIATES THEREOF | ZENECA LIMITED (GB) | 1993-09-30 | — | — | WO | disclosed |
| EP-0186252-B1 | USE OF THIOPHENE COMPOUNDS FOR THE MANUFACTURE OF A MEDICAMENT AGAINST TUMOURS | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1992-04-01 | — | — | EP | disclosed |
| US-4978674-A | ANTIARRHYTHMIA AGENTS | KOTOBUKI SEIYAKU CO. LTD. (JP) | 1990-12-18 | — | — | US | disclosed |
| US-4767758-A | RADIOSENSITIZING CELLS; BLOCKING REACTION OF OXYGEN RADICALS | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1988-08-30 | — | — | US | disclosed |
| EP-0186252-A2 | Use of thiophene compounds for the manufacture of a medicament against tumours | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1986-07-02 | — | — | EP | disclosed |
| US-4220793-A | Process for preparing a thiophene derivative | LABAZ (FR) | 1980-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | DAO 940/4885CA1 3193/4885CA2 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.